SUTRO BIOPHARMA INC.

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

15 May 2023 05:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

08 May 2023 05:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

27 Apr 2023 13:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

18 Apr 2023 10:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

30 Mar 2023 13:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 Mar 2023 13:01:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference

01 Mar 2023 05:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer  

28 Feb 2023 05:00:03 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 Feb 2023 13:01:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

09 Jan 2023 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 05:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

21 Dec 2022 05:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

20 Dec 2022 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

10 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

23 Nov 2022 04:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones

08 Nov 2022 13:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

03 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

02 Nov 2022 04:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Departure of Chief Medical Officer

24 Oct 2022 04:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference

01 Sep 2022 04:00:01 By Nasdaq GlobeNewswire